The abstract is read at the publisher; the summary is JClub's.
EBV infection in over 95% of the global population is linked to multiple cancers and autoimmune diseases, with co-infections reshaping latency–lytic balance and disease risk.
- Why it matters: Current clinical treatments mainly address active pathogens, leaving latent EBV reservoirs untouched, which limits prevention and treatment of EBV-driven progression.
- What they did: The review synthesizes evidence on how co-infections with Helicobacter pylori, human immunodeficiency virus, human papillomavirus, and Plasmodium falciparum can alter host immunity and latency–lytic balance, and discusses emerging latent-targeting approaches.
- The result: Pathogen interactions are proposed to exacerbate chronic inflammation, immunosuppression, and epigenetic dysregulation, supporting the need for further research to improve prevention and therapies targeting latent EBV.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.